[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589661":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":37,"responsibleParty":120,"collaborators":12,"id":122,"slug":123,"hasResults":124,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":12,"eligibilityCriteria":128,"healthyVolunteers":124,"sex":129,"minAge":130,"maxAge":12,"enrollmentInfo":131,"targetDuration":12,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":40,"whyStopped":12,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Arm","NO_INTERVENTION","Participants randomized to the control group will receive tarlatamab administration as per usual care.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Hospital-at-Home\u002FHAH Intervention Arm","EXPERIMENTAL","Participants randomized to the intervention group will receive tarlatamab administration through the hospital-at-home care delivery model.",[18],"Other: Hospital-at-Home\u002FHAH",[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":12},"Hospital-at-Home\u002FHAH","After discharge, a SeniorCare community paramedic will provide a home visit to the participant's home or residence",[14],[25],{"name":26,"affiliation":5,"role":27},"Robert Daly, MD, MBA","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":32},"CONTACT","646-608-3789","dalyr1@mskcc.org",{"name":34,"role":30,"phone":35,"phoneExt":12,"email":36},"Michael Offin, MD","646-608-3763","offinm@mskcc.org",[38,54,65,76,88,99,109],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-74.54932,40.70621,{"lat":50,"lon":49},[53],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":12},{"facility":55,"status":40,"city":56,"state":42,"zip":57,"country":44,"countryCode":45,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Memorial Sloan Kettering Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":47,"coordinates":59},[60,61],-74.11709,40.39428,{"lat":61,"lon":60},[64],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":12},{"facility":66,"status":40,"city":67,"state":42,"zip":68,"country":44,"countryCode":45,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Memorial Sloan Kettering Bergen (Limited Protocol Activities)","Montvale","07645",{"type":47,"coordinates":70},[71,72],-74.02292,41.04676,{"lat":72,"lon":71},[75],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":12},{"facility":77,"status":40,"city":78,"state":79,"zip":80,"country":44,"countryCode":45,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":47,"coordinates":82},[83,84],-73.29289,40.84288,{"lat":84,"lon":83},[87],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":12},{"facility":89,"status":40,"city":90,"state":79,"zip":91,"country":44,"countryCode":45,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Memorial Sloan Kettering Westchester (Limited Protocol Activities)","Harrison","10604",{"type":47,"coordinates":93},[94,95],-73.71263,40.96899,{"lat":95,"lon":94},[98],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":12},{"facility":100,"status":40,"city":79,"state":79,"zip":101,"country":44,"countryCode":45,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Memorial Sloan Kettering Cancer Center (All Protocol Activites)","10065",{"type":47,"coordinates":103},[104,105],-74.00597,40.71427,{"lat":105,"lon":104},[108],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":12},{"facility":110,"status":40,"city":111,"state":79,"zip":112,"country":44,"countryCode":45,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Memorial Sloan Kettering Nassau (Limited Protocol Activities)","Uniondale","11553",{"type":47,"coordinates":114},[115,116],-73.59291,40.70038,{"lat":116,"lon":115},[119],{"name":26,"role":30,"phone":31,"phoneExt":12,"email":12},{"type":121,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100589661","a-study-of-hospital-at-home-for-people-receiving-tarlatamab-100589661",false,"NCT06957314","A Study of Hospital-at-Home for People Receiving Tarlatamab","MATCHES-Novel: MAking Telehealth Delivery of Cancer Care at Home Effective and Safe for Novel Therapies: A Hospital-at-Home Model for Tarlatamab Delivery","Inclusion Criteria:\n\nPatient\n\n* Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)\n* Treatment plan of commercially available tarlatamab monotherapy as standard of care\n* Patients must be 18 years of age or older\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C2\n* Patients must have adequate organ and bone marrow function, defined by the following laboratory results obtained within 28 days prior to the first study treatment:\n\n  * ANC ≥ 1000 cells\u002FμL (without granulocyte colony stimulating factor support within 4 weeks prior to Cycle 1, Day 1)\n  * Platelet count ≥50,000\u002FμL (without transfusion within 4 weeks prior to Cycle 1, Day 1)\n  * Hemoglobin ≥8.0 g\u002FdL (without transfusion within 4 weeks prior to Cycle 1, Day 1)\n  * Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3 X upper limit of normal (ULN). Serum bilirubin ≤ 1.5 x ULN. Patients with known Gilbert disease who have serum bilirubin level ≤ 2 x ULN may be enrolled.\n  * Estimated Glomerular Filtration Rate (eGFR) ≥ 30mL\u002Fmin using the CKD-EPI formula.\n* The patient is willing to give and sign informed consent\n* Appropriate homebound setting as defined by one of the following:\n\n  * Lodging at MSK Residence or hotel\n  * 5 New York City boroughs, lower Westchester County (northern boundary Cross County Parkway) and Nassau County (eastern boundary Wantagh State Parkway). This is based on the community paramedic (SeniorCare) 60-minute response time catchment area. If there is any uncertainty about patient residence eligibility, the Principal Investigator will decide after discussion with SeniorCare.\n* Patients must be accompanied by a caregiver for the period of time the patient is enrolled in the HaH intervention. For cases where there is uncertainty, the Principal Investigator will make the final determination.\n\nCaregiver\n\n* Primary caregiver as identified by patient enrolled on study\n\nPhysician\n\n* Treating physician for patient(s) enrolled on study; managing treatment plan of commercially available tarlatamab as standard of care\n\nExclusion Criteria:\n\nPatient\n\n* Patients with a documented active infection prior to starting tarlatamab. This includes grade 3 or higher viral, bacterial, or fungal infection.\n* Patients with baseline dementia or cognitive barriers\n* Uncontrolled arrhythmias\n\nCaregiver\n\n* Caregiver deemed inappropriate by treating physician\n\nPhysician\n\n* No exclusion criteria","ALL","18 Years",{"count":132,"type":133},70,"ESTIMATED","INTERVENTIONAL",[136],"NA","The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).",[139,140],"Small-cell Lung Cancer","Small Cell Lung Carcinoma",[139,140,142,5,143,144],"Tarlatamab","25-077","extensive stage small cell lung cancer","2026-06-11",{"date":147,"type":148},"2026-06-12","ACTUAL",{"date":150,"type":148},"2025-04-23",{"date":152,"type":133},"2028-04-23",{"name":5,"class":6},7]